431 reports of this reaction
2.3% of all THIOTEPA reports
#8 most reported adverse reaction
ACUTE GRAFT VERSUS HOST DISEASE is the #8 most commonly reported adverse reaction for THIOTEPA, manufactured by Amneal Pharmaceuticals LLC. There are 431 FDA adverse event reports linking THIOTEPA to ACUTE GRAFT VERSUS HOST DISEASE. This represents approximately 2.3% of all 18,516 adverse event reports for this drug.
Patients taking THIOTEPA who experience acute graft versus host disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE GRAFT VERSUS HOST DISEASE is a less commonly reported adverse event for THIOTEPA, but still significant enough to appear in the safety profile.
In addition to acute graft versus host disease, the following adverse reactions have been reported for THIOTEPA:
The following drugs have also been linked to acute graft versus host disease in FDA adverse event reports:
ACUTE GRAFT VERSUS HOST DISEASE has been reported as an adverse event in 431 FDA reports for THIOTEPA. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE GRAFT VERSUS HOST DISEASE accounts for approximately 2.3% of all adverse event reports for THIOTEPA, making it a notable side effect.
If you experience acute graft versus host disease while taking THIOTEPA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.